SEARCH

SEARCH BY CITATION

References

  • 1
    Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 10960-1993. J Rheumatol 1997; 24: 7380.
  • 2
    Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 3750.
  • 3
    Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311322.
  • 4
    Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and indices regression of established fibrosis. Arthritis Rheum 2009; 60: 219224.
  • 5
    Tamaki Z, Asano Y, Hatano M, et al. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol 2012; 22: 9499.
  • 6
    Spiera R, Gordon J, Mersten J, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2001; 70: 10031009.
  • 7
    Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58: 25432548.
  • 8
    Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009; 60: 584591.
  • 9
    Divekar AA, Khanna D, Abtin F, et al. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clin Immunol 2011; 141: 293303.
  • 10
    Khanna D, Saggar R, Mayes MD, et al. Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSc-ILD). Arthritis Rheum 2011; 63: 35403546.
  • 11
    Arora B, Kumar L, Sharma A, et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004; 15: 358359.
  • 12
    Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI-571) in Philadelphia chromosome positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201206.